1/41
Looks like no tags are added yet.
Asthma
PP: airway inflammation+hyperresponsiveness
CM+DX: wheeze
SOB
cough
chest tightness
+
confirmed variable expiratory airflow limitation
-FEV1→reduced
-PFT→excessive variability in lung fxn
Asthma Assessment
asthma control
tx issues
inhaler technique
adherence
side effects
attitude towards tx
comorbidities
rhinitis
rhinosinusitis
GERD
obesity
OSA
depression
anxiety
Asthma Tx Format
1st line/preferred→track 1
1+2: inhaled budesonide/fluticasone+formoterol PRN
-sxs u4-5 days/week
3: low-dose budesonide/fluticasone+formoterol MART
4: medium-dose budesonide/fluticasone+formoterol
5: add tiotropium
pulmonary referral
high-dose budesonide/fluticasone+formoterol
anti-IgE
anti-IL5/5R
anti-IL4Ra
anti-TSLP
reliever→low-dose budesonide/fluticasone+formoterol PRN
track 2
1: budesonide/fluticasone+albuterol PRN
-sxs u 2 times/month
2: low-dose budesonide/fluticasone
-sxs u 2 times/month<x<4-5 days/week
3: low-dose budesonide/fluticasone+formoterol/salmeterol
4: medium-dose budesonide/fluticasone+formoterol/salmeterol
5: add tiotropium
pulm referral
high-dose budesonide/fluticasone+formoterol/salmeterol
anti-IgE
anti-IL5/5R
anti-IL4Ra
anti-TSLP
reliever→budesonide/fluticasone+albuterol PRN
Beta-2 Agonists
MX:
short acting (SABA)
albuterol
levalbuterol
long acting (LABA)
Fluticasone propionate (Flovent DISKUS, Flovent) | 50 mcg 125 mcg 250 mcg |
Salmeterol (Serevent) | 50 mcg |
Budesonide (Pulmicort Turbuhaler) | 100 mcg 200 mcg 400 mcg |
Formoterol (Oxeze Turbuhaler) |
MOA: relaxes airway smooth muscle
Initiation Step 3
track 1
sx x most days
or
waking asthma x 1+/week
tx→low dose ICS-formoterol+low-dose ICS formoterol reliever PRN
track 2
sx x most days
or
waking asthma x 1+/week
tx→low dose ICS-LABA+SABA reliever PRN
Initiation Step 4
track 1
sx x daily
or
waking with asthma 1+/week+low lung fxn
tx→medium-dose ICS-formoterol+low-dose ICS-formoterol reliever PRN
severe+uncontrolled tx→PO corticosteroids
track 2
sx x daily
or
waking with asthma 1+/week+low lung fxn
tx→medium/high-dose ICS-LABA+SABA reliever PRN
severe+uncontrolled tx→PO corticosteroids
Initiation Step 5
track 1
severely uncontrolled sx
exacerbations with tx
tx→medium-dose ICS-formoterol+LAMA
or
high-dose ICS-formoterol
refer for phenotype assessment
track 2
severely uncontrolled sx
exacerbations with tx
tx→medium/high dose ICS-LABA+LAMA
or
high-dose ICS-LABA
refer for phenotype assessment
Antimuscarinics
MX:
SAMA
ipatropium
LAMA
glycopyrrolate
umeclidinium
tiotropium
aclidinium
revefenacin
I: COPD
ROA: inhalation
LAMA+LABA+ICS Combinations
MX: umeclinidium+fluticasone+furoate+vilanterol
glycopyrrolate+formoterol+budesonide
I: COPD
ROA: U→daily
G→BID
Asthma Peds Tx (6-11 y/o)
track 1
low-dose ICS+SABA
low-dose inhaled corticosteroid
low-dose ICS-LABA
or
medium-dose ICS
or
very low-dose ICS-formoterol maintenance and reliever (MART)
medium-dose ICS-LABA
or
low-dose ICS formoterol+reliever therapy (MART)
phenotype assessment referral high-dose ICS-LABA
or
anti IgE
or
anti-IL4R
reliever→SABA/ICS-formoterol reliever (MART)
track 2
low-dose ICS
low-dose ICS+SABA
low dose ICS+LTRA
+biotropium
or
+LTRA
+anti-IL5
or
low-dose PO corticosteroids
reliever→SABA/ICS-formoterol reliever (MART)
Chronic+Severe Asthma Tx
anti-IgE→omalizumab
anti-IL5/anti-IL5R:
benralizumab
mepolizumab
reslizumab
anti-IL4R→dupilumab
anti-TSLP→tezepelumap
Special Populations: Pregnancy
active tx outweighs side effects
tx exacerbations aggressively
Special Populations: Rhinitis+Sinusitis
associated with more severe asthma
Special Populations: Obesity
more difficult to control
tx plan→add losing weight (5-10%)
Special Populations: Elderly
comorbidities
arthritis
eyesight
inspiratory flow
tx complexity
Special Populations: Gastroesophageal Reflux
common additional/concomitant condition
Special Populations: Anxiety+Depression
help pt distinguish asthma vs anxiety sx
Special Populations: Aspirin-Exacerbated Respiratory Disease
TX: ICX
OCS
LTRA
no: ASA/aspirin
NSAIDS
Special Populations: Food Allergy+Anaphylaxis
rarely trigger for asthma
specialist referral
Special Populations: Surgery
good asthma control needs to be achieved before operation whenever possible
may require intra-operative hydrocortisone→reduce adrenal crisis risk
Asthma Exacerbation Classifications
worsening in sx+lung fxn
mild-moderate
talks in phrases
prefers sitting-lying
not agitated
increased RR
no accessory muscles
HR: 100-120 bpm
O2 sat: 90-95%
predicted PEF: 50%+
severe
talks in words
sits hunched forward
agitated
RR: over 30+ bpm
accessory muscle use
HR: 120+ bpm
O2 sat: u90%
predicted PEF: 50%+
life-threatening
drowsy
confused
silent chest
Asthma Exacerbation Tx
mild-moderate
NP: assess for discharge
-improved sx
-no SABA needed
-improving PRF
-O2 sat 94%+
-adequate resources at home
evaluate inhaler technique/adherence
MX: pMDI SABA 4-10 puffs x q20mins for 1hr
prednisolone x 5-7 days
O2 tx
severe/life-threatening/worsening mild-moderate
NP: acute care facility
O2
intubation
MX: nebulized albuterol+ipatropium q4-6h
IV corticosteroids
PO corticosteroids
tx fail→IV magnesium x 1 dose
COPD
PP: persistent respiratory sx
airflow limitation
E: airway abnormalities
alveolar abnormalities
noxious particles
gases
impaired lung growth
lung+systemic infxn
CM: cough
dyspnea
sputum production
DX:
FEV1/FVC→u0.70
inspiratory flow rate→u60L/min
alpha-1 antitrypsin deficiency (AATD)→u20%→deficient variant
-F
-I
-S
-Z
GOLD grade
exacerbation hx
mMRC/CAT
COPD NP Tx+Vaccines
NP:
stop smoking
reduce exposure to irritants/pollutants
pulmonary rehabilitation
O2 tx PRN
Vax:
influenza
SARS-CoV-2
20-valent pneumococcal conjugate
15-valent pneumococcal conjugate+23-valent pneumococcal polysaccharide
tdap
RSV
50+ y/o→zoster
COPD Mx Tx
0-1 moderate exacerbations+no hospitalization
mMRC 0-1/CAT u10→A bronchodilator
mMRC 2+/CAT 10+→LABA+LAMA
2+ moderate exacerbation/1+hospitalization
LABA+LAMA
blood eos 300+→LABA+LAMA+ICS
Bronchodilators (General)
increase FEV1
change other spirometric variables
alter airway smooth muscle→widen airways→improve expiratory flow
reduce dynamic hyperinflation
improve exercise tolerance
MX
beta2 agonists
antimuscarinics
methylxanthines
Beta 2 Agonists
MX:
short acting beta2 agonists (SABA)
albuterol
levalbuterol
long acting beta2 agonists (LABA)
formoterol
aformoterol
indacaterol
salmeterol
olodaterol
MOA: stimulates beta2 adrenergic receptors→increases cyclic AMP→antagonizes bronchoconstriction→relaxes smooth muscle of airway
I: COPD
formoterol→COPD+asthma
ROA:
SABA
1-2 inhalations q4-6 hrs PRN
LABA
F+AF+S→BID
I→daily
O→twice daily
duration
short acting beta2 agonists (SABA)→4-6hrs
long acting beta2 agonists (LABA)→12-24hrs
AE: resting sinus tachycardia
precipitate arrhythmias
BP increased
glucose increased
IOP increased
hypokalemia
CNS simulation/excitation→seizures
Antimuscarinics
MX:
short-acting antimuscarinics (SAMA)
ipatropium
long-acting antimuscarinics (LAMA)
glycopyrrolate
umeclidinium
tiotropium
aclidinium
revefenacin
SAMA-SABA combination
ipatropium bromide-albuterol
LAMA-LABA combination
umeclidinium-vilanterol
glycopyrrolate-formoterol fumarate
tiotropium bromide-olodaterol
indacterol-glycopyrrolate inhalation
MOA: blocks bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors→bronchodilation
blocks inhibitory neuronal receptor M2→vagally-induced bronchoconstriction
located on bronchial smooth muscle
I: COPD
ROA:
short-acting antimuscarinics (SAMA)
more pronounced effect on M2
2 inhalations QID
long-acting antimuscarinics (LAMA)
prolonged binding to M3→longer duration
dissociated more quickly from M2 receptors
BID→daily dosing
U+R→daily
G+T+A→BID
I-A→QID
SAMA-SABA combinations
QID
LAMA-LABA combinations
U-V→daily
G-FF+TB-O+I-GI→BID
AE: poorly absorbed (anticholinergic)
dry mouth
bitter/metallic taste (ipatropium)
small increase in CV events (ipatropium)
urinary sx
Methylxanthines
MX: theophylline
MOA: non-selective phosphodiesterase inhibitors→weak bronchodilation
requires high plasma concentrations
ROA: daily
IR→q6-8 hrs
12-hr ER→q12 hrs
24-hr ER→daily
tolerated x 3 days→increase dose→tolerate 3 more days→increase dose
I: COPD
AE: many pts can’t tolerate
RF→overdose
atrial+ventricular arrhythmias
grand mal convulsions
headaches
insomnia
nausea
heartburn
CI: erythromycin
ciprofloxacin
allopurinol
cimetidine
fluvoxamine
zileuton
Inhaled Corticosteroids
MX:
ICS
flunisolide
cicloesonide
fluticasone furoate
mometasone
fluticasone propionate
budesonide
beclomethasone
LAMA-ICS combination
fluticasone propionate-salmeterol
budenoside-formoterol fumarate dihydrate
mometasone furoate-formoterol fumarate dihydrate
fluticasone furoate-vilaterol
LAMA-LABA-ICS combination
umeclidinium-fluticasone furoate-vilanterol
glycopyrrolate-formoterol-budesonide
MOA:
anti inflammatory
blocks late reaction to allergen
reduces airway hyper-responsiveness
inhibits:
cytokine production
adhesion
protein activation
inflammatory cell migration+activation
reverse beta-2 receptor downregulation
inhibits microvascular leakage
I:
ICS
COPD exacerbation+hospitalization
2+ moderate COPD exacerbations/year
eosinophils 300+ cells/microL
concomitant asthma
asthma hx
LAMA-ICS combination
COPD
asthma
LAMA-LABA-ICS combination
COPD
ROA:
ICS
inhalation
LAMA-ICS combination
FP-S+B-FFD+MF-FFD→BID
FF-V→daily
LAMA-LABA-ICS combination
U-FF-V→daily
G-F-B→BID
AE: PO candidiasis
hoarse voice
skin bruising
pneumonia
CI: repeat pneumonia
eosinophils u100 cells/microL
mycobacterial infxn hx
PO Glucocorticoids
MOA: reduce tx failure rate
reduce relapse rate
improve lung fxn
decrease breathlessness
I: acute exacerbations in hospitalized pts
ED
short-term
ROA: duration→5-7 days
AE: many AEs
no benefits
high rate of systemic complications
Phosphodiesterase-4 Inhibitors
MX: roflumilast
MOA: inhibits breakdown of intracellular cyclic AMP→reduces inflammation+improve lung fxn+decreases COPD exacerbation risk
I: severe-very severe COPD (predicted FEV1 u50%)
chronic bronchitis
hx of frequent COPD exacerbations
ROA: daily x 4 weeks→daily
AE: diarrhea
nausea
reduced appetite
weight loss
abdominal pain
sleep disturbance
headache
suicidality
CI: underweight
depression
Mucolytics
MX: carbocystiene
N-acetylcysteine
MOA: reduce sputum viscosity
promote expectoration
regular use→reduce exacerbation+modestly improve health status
I: COPD+no ICS
Antibiotics (For COPD)
MX: azythromycin
erythromycin
MOA: anti-inflammatory properties
may reduce rate of exacerbations
not used for antimicrobial properties
I: COPD exacerbation-prone pts
ROA:
A
daily x 1 year
TIW x 1 year
E→BID x 1 year
COPD NP Tx
pulmonary rehabilitation
self-management
integrated care programs
physical activity
exercise training
nutritional suport
O2 tx+ventilatory support
COPD Exacerbations Tx
NP: acute respiratory failure+no CIs→non-invasive mechanical ventilation
MX: nebulizer/inhaler SABA q4-6h
nebulizer/inhaler SABA+SAMA q4-6h
nebulizer/inhaler SAMA q4-6h
severe exacerbations→systemic corticosteroids→IV methylprednisolone q8h
-less severe→PO
-no more than 5 days
PO azithromycin daily x 3 days
PO azythromycin x taper up
Nebulizers
jet nebulizers
compressed gas passes through a jet with aerosolized mx
10-20%→deposited in respiratory tract
I→bronchodilator tx
mesh nebulizers
multiple apertures to produce aerosol
up+down movement through mesh→inhale mx
vibrating mesh/horn
expensive
not for bronchodilator tx
ultrasonic nebulizers
uses pizoelectric crystal
vibrates at high frequency→creates inhalable droplets
Pressurized Metered Dose Inhalers (pMDI) Key Components+Benefits+Limitations
key components
canister
propellant (HFA)
mx formulation
metering valve
actuator
benefits
small size
portability
convenience
multi dose capability
rapid dose delivery
contents protected from contamination
limitations
mx delivery depends on pt technique
misuse→suboptimal lung deposition of mx
pMDI Technique
process
prime the inhaler per manufacturer instructions
shake inhaler to mix expectorant+medication
take cap off mouthpiece+examine for any foreign objects
exhale through mouth→push out all air from lungs→close lips around mouthpiece+form a tight seal
while pushing down on canister inhale deeply+slowly at same time
hold breath for 10 seconds or as long as possible
exhale slowly
compared with breath-actuated MDI
releases mist of mx when person inhales
must seal lips around mouthpiece+breathe in deeply with a steady amount of force
Spacers+Valved Holding Chambers
both direct mx into lungs+improve pt technique
spacer
simple tube/extension
contains aerosol plume actor pMDI actuation
valved holding chambers
extension device than contains one-way valves to hold aerosol until inhalation
more useful than spacer in poor hand-breath coordination pts
decreases oropharyngeal deposition
used with pMDI
recommended use:
-children
-adults with difficulty with technique
Dry Powder Inhaler
MX: aerolizer
diskus
ellipta
flexhaler
handihaler
neohaler
pressair
rotahaler
turbuhaler
twisthaler
handihaler
creates aerosol when inhaled air is drawn through a powdered mx
-powder contains micronized mx particles
-must be disaggregated to under 5 microns
requires high inspiratory flow (30-120L/min) to appropriately disaggregate particles+overcome device resistance
devices requiring more/less inspiratory flow
highest resistance→handihaler
lowest resistance→ellipta
avoid use
very young/ill children
weak pts
older pts
altered mental status pts
Rescue Inhaler+Maintenance Inhalers
rescue inhaler+LABA
PRN
tx acute sxs
-wheezing
-dyspnea
-etc.
short-acting→x4-6 hrs
maintenance inhaler+LABA
daily
prophx→acute sxs/exacerbations
long-acting→ x12-24 hrs